Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in gastric cancer.
환자-대조
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: GC (HR = 1
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The findings of this study indicate that the expression levels of Piezo1 and Piezo2 have the potential to serve as diagnostic indicators or therapeutic targets for GC management. [TRIAL REGISTRATION] CRD42023495836 (PROSPERO).
[BACKGROUND] This study aims to investigate the expression pattern and clinical significance of Piezo1 and Piezo2 in various cancers, focusing on gastric cancer (GC).
- p-value p < 0.05
- p-value p < 0.0001
- OR 1.87
- HR 1.48
- 연구 설계 case-control
APA
Liang T, Wang J, et al. (2025). Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in gastric cancer.. Discover oncology, 16(1), 582. https://doi.org/10.1007/s12672-025-02309-5
MLA
Liang T, et al.. "Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in gastric cancer.." Discover oncology, vol. 16, no. 1, 2025, pp. 582.
PMID
40257604 ↗
Abstract 한글 요약
[BACKGROUND] This study aims to investigate the expression pattern and clinical significance of Piezo1 and Piezo2 in various cancers, focusing on gastric cancer (GC).
[METHODS] The study investigated the mRNA expression levels of Piezo1 and Piezo2 in tumor samples from different cancers using the BEST online database. The case-control studies about the relation between Piezo1 and Piezo2 and GC were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. The retrieval time was from inception to October, 2023. The meta-analysis of the included literatures was conducted by the STATA 12.0 software. Additionally, the expression profiles of Piezo1 and Piezo2 in tumor and normal gastric tissues were analyzed, and their clinical drug relevance was assessed using the CPADS database. The research program has been registered with PROSPERO (CRD42023495836).
[RESULTS] The analysis demonstrated elevated mRNA expression of both Piezo1 and Piezo2 in the majority of tumor samples. Of particular note was the significant increase observed in GC tissue compared to normal tissue (all p < 0.05). Additionally, the meta-analysis revealed a meaningful correlation between high expression levels of Piezo1 and Piezo2 and poor prognosis in patients with GC (HR = 1.48, 95% CI = 1.27-1.69, p < 0.0001). This study identified a significant correlation between high levels of Piezo1 expression and the TNM phase (OR = 1.87, 95% CI = 1.21-2.91, p = 0.005). Furthermore, enhanced Piezo2 expression was observed to be positively correlated with survival status (OR = 2.12, 95% CI = 1.31-3.44, p = 0.002). Piezo1 (p = 0.028, R = 0.12) and Piezo2 (p = 0.049, R = 0.09) have been identified as potential therapeutic targets for GC treatment, according to drug sensitivity analyses.
[CONCLUSION] The findings of this study indicate that the expression levels of Piezo1 and Piezo2 have the potential to serve as diagnostic indicators or therapeutic targets for GC management.
[TRIAL REGISTRATION] CRD42023495836 (PROSPERO).
[METHODS] The study investigated the mRNA expression levels of Piezo1 and Piezo2 in tumor samples from different cancers using the BEST online database. The case-control studies about the relation between Piezo1 and Piezo2 and GC were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. The retrieval time was from inception to October, 2023. The meta-analysis of the included literatures was conducted by the STATA 12.0 software. Additionally, the expression profiles of Piezo1 and Piezo2 in tumor and normal gastric tissues were analyzed, and their clinical drug relevance was assessed using the CPADS database. The research program has been registered with PROSPERO (CRD42023495836).
[RESULTS] The analysis demonstrated elevated mRNA expression of both Piezo1 and Piezo2 in the majority of tumor samples. Of particular note was the significant increase observed in GC tissue compared to normal tissue (all p < 0.05). Additionally, the meta-analysis revealed a meaningful correlation between high expression levels of Piezo1 and Piezo2 and poor prognosis in patients with GC (HR = 1.48, 95% CI = 1.27-1.69, p < 0.0001). This study identified a significant correlation between high levels of Piezo1 expression and the TNM phase (OR = 1.87, 95% CI = 1.21-2.91, p = 0.005). Furthermore, enhanced Piezo2 expression was observed to be positively correlated with survival status (OR = 2.12, 95% CI = 1.31-3.44, p = 0.002). Piezo1 (p = 0.028, R = 0.12) and Piezo2 (p = 0.049, R = 0.09) have been identified as potential therapeutic targets for GC treatment, according to drug sensitivity analyses.
[CONCLUSION] The findings of this study indicate that the expression levels of Piezo1 and Piezo2 have the potential to serve as diagnostic indicators or therapeutic targets for GC management.
[TRIAL REGISTRATION] CRD42023495836 (PROSPERO).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (4)
- Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.
- Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations.
- Meta-analysis and Database Validation of Exosomal MicroRNAs and Prognosis in Gastric Cancer Patients.
- Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- Multicenter Validation Study of the Clinical Diagnostic Criteria for IgG4-Related Sclerosing Cholangitis 2020 in Japan.